Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogenic Mononuclear Cord Blood Cells in Acute Severe Spinal Cord Injury
NCT05693181Phase 2Unknown
- Sponsor
- Sklifosovsky Research Institute for Emergency Medicine
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic mononuclear cord blood cells in spinal cord injury (SCI), sponsored by Sklifosovsky Research Institute for Emergency Medicine. Status: unknown.
02
Drugs
allogeneic mononuclear cord blood cells
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT05693181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05693181.